Parasramani Srichand G, Vishwanath Vishalakshi, Ghia Deepti, Gandhi Miti R, Dhoot Dhiraj, Barkate Hanmant
Dermatology, Anisha Clinic, Mumbai, IND.
Dermatology, Rajiv Gandhi Medical College and Chhatrapati Shivaji Maharaj (CMS) Hospital, Mumbai, IND.
Cureus. 2022 Nov 30;14(11):e32035. doi: 10.7759/cureus.32035. eCollection 2022 Nov.
Introduction Although seborrheic dermatitis (SD) is not lethal, it has a significant impact on the quality of life. Many cases of SD are managed with ketoconazole, but luliconazole has shown an equivalent or lower minimum inhibitory concentration (MIC), but not many studies have been done for its efficacy and safety in SD. With this in mind, we set out to conduct a study comparing the effectiveness, safety, and tolerability of Lulican™ (luliconazole 1% + salicylic acid 3% + ZPTO 1%) shampoo and Ketoconazole (Ketoconazole 2% + ZPTO 1%) shampoo in the treatment of SD. Materials and methods In this prospective, randomized, multi-center study, mild to moderate scalp SD patients were prescribed Lulican™ or Ketoconazole shampoo three times a week for a duration of four weeks. Effectiveness assessment was done with the Seborrheic-Dermatitis-Severity-Score (SDSS) and Physician-Global-Assessment (PGA), and quality of life was assessed with the help of the Scalpdex-23 questionnaire. Results At four weeks, 68% and 57.9% reduction was seen in SDSS in Lulican™ and Ketoconazole shampoo, respectively. Moreover, 58% and 44% of patients achieved excellent to moderate responses as per PGA with Lulican™ and ketoconazole shampoo, respectively. For safety, no statistical difference was reported, but product tolerability and subjective cosmetic acceptability were significantly better in the Lulican™ group as compared to the Ketoconazole group at the end of four weeks. The mean Scalpdex-23 score at week four was reduced by 35.7% and 21.1% in Lulican™ and ketoconazole groups, respectively (p<0.05). Conclusion While both treatments were successful in alleviating SD symptoms and were well tolerated, Lulican™ stood out as a preferred treatment option due to better quality of life (QoL) improvement in SD.
引言 虽然脂溢性皮炎(SD)并非致命性疾病,但它对生活质量有显著影响。许多脂溢性皮炎病例使用酮康唑进行治疗,而卢立康唑已显示出相同或更低的最低抑菌浓度(MIC),但针对其治疗脂溢性皮炎的疗效和安全性的研究并不多。考虑到这一点,我们开展了一项研究,比较卢立肯™(卢立康唑1% + 水杨酸3% + 硫代吡啶锌1%)洗发水和酮康唑(酮康唑2% + 硫代吡啶锌1%)洗发水治疗脂溢性皮炎的有效性、安全性和耐受性。
材料与方法 在这项前瞻性、随机、多中心研究中,轻度至中度头皮脂溢性皮炎患者被处方每周使用三次卢立肯™或酮康唑洗发水,持续四周。使用脂溢性皮炎严重程度评分(SDSS)和医生整体评估(PGA)进行有效性评估,并借助头皮指数 - 23问卷评估生活质量。
结果 四周时,卢立肯™和酮康唑洗发水组的SDSS分别降低了68%和57.9%。此外,根据PGA评估,分别有58%和44%的患者使用卢立肯™和酮康唑洗发水后达到了优至中度反应。在安全性方面,未报告有统计学差异,但在四周结束时,卢立肯™组的产品耐受性和主观美容可接受性明显优于酮康唑组。四周时,卢立肯™组和酮康唑组的头皮指数 - 23平均得分分别降低了35.7%和21.1%(p<0.05)。
结论 虽然两种治疗方法都成功缓解了脂溢性皮炎症状且耐受性良好,但由于卢立肯™在改善脂溢性皮炎患者生活质量(QoL)方面表现更佳,因此它是首选的治疗方案。